All of these drugs are injectables. A total of 63 oral GLP-1 receptor drugs are in development, with four phase 3 products competing for the first approval of an oral version of the drug. Novo Nordisk ...

The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...

The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...

Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...

Rybelsus in combination with standard T2DM therapy reduced the risk of major cardiovascular events by 14% in patients with ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

The Biden administration is proposing a rule that would require Medicare and Medicaid to cover weight-loss drugs, potentially ...

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come KELOW ...

Today's GLP-1 drug market consists primarily of semaglutide (Wegovy®, Ozempic®, and Rybelsus®), owned by Novo Nordisk®; and tirzepatide (Zepbound®, Mounjaro®), owned by Eli Lilly™. All five of those ...

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November ...

In this study, almost 70% of respondents were taking semaglutide (Ozempic, Rybelsus, Wegovy) and nearly a quarter were taking ...

GLP-1 weight loss medications work, in part, by turning folks off foods they used to enjoy. That's leading to more food ...